BeOne Newsroom
Media Resources
Corporate Press Kits
Review resources about BeOne, formerly BeiGene.
Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.
Media Library
View and download images of our leaders, facilities, company logo and other corporate assets.
Press Releases
Read our latest news.
-
July 10, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma — New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival Second approval for TEVIMBRA in…
-
July 10, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma — New indication based on results of RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival Second approval for TEVIMBRA in…
-
July 7, 2025
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025
-
July 3, 2025
GRANT OF RESTRICTED SHARE UNITS
-
July 2, 2025
Next Day Disclosure Return
-
June 26, 2025
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day — BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising…
-
June 26, 2025
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day — BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising…
-
June 25, 2025
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA® — BASEL, Switzerland–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the…
-
June 25, 2025
BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA® — BASEL, Switzerland–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the…
-
June 13, 2025
GRANT OF SHARE OPTIONS, RESTRICTED SHARE UNITS AND PERFORMANCE SHARE UNITS
-
June 12, 2025
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 — Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and…
-
June 12, 2025
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025 — Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and…
Congress Hub
Review the latest information about the data we’re presenting and where you can find us.
Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More
Our Pipeline
Our broad and deep cancer pipeline is one of the largest in the industry.